Lercanidipine: Short Plasma Half-life, Long Duration of Action and High Cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties-Reference-Cited by-同舟云学术

Lercanidipine: Short Plasma Half-life, Long Duration of Action and High Cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties

Published:1998-01 Issue:sup2 Volume:7 Page:10-17
ISSN:0803-7051
Container-title:Blood Pressure
language:en
Short-container-title:Blood Pressure

Author:

HERBETTE LEO G.,VECCHIARELLI MICHELLE,LEONARDI AMEDEO

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/080370598438998

Reference20 articles.

1. Molecular interaction between lacidipine and biological membranes

2. Atherogenic activity of excess membrane cholesterol in arterial smooth muscle and endothelial cells

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-inflammatory efficacy of lercanidipine hydrochloride on TNF-α induced HaCaT cells and TPA-induced acute mouse ear inflammation model;Archives of Dermatological Research;2024-07-24

2. New Insights into the Nephroprotective Potential of Lercanidipine;International Journal of Molecular Sciences;2023-09-13

3. Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases;Journal of Personalized Medicine;2022-08-10

4. Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial function;Cholesterol;2022

5. Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington's disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways;Neurochemistry International;2019-12